WY-14643 (Pirinixic Acid): PPARα Agonist Driving Liver Regeneration & Metabolic Innovations

Introduction

The peroxisome proliferator-activated receptor alpha (PPARα) pathway has emerged as a linchpin in metabolic disorder research, with far-reaching implications for lipid metabolism regulation, inflammation, and tissue regeneration. WY-14643 (Pirinixic Acid), a highly potent and selective PPARα agonist, stands at the forefront of these discoveries. While prior reviews have highlighted its dual PPARα/γ agonism and roles in immunometabolic signaling within the tumor microenvironment, this article offers a distinct, in-depth perspective: we focus on the molecular mechanics of WY-14643-mediated liver regeneration and its translational potential in metabolic research, integrating breakthrough findings on YAP-TEAD signaling and insulin sensitivity enhancement. This approach delivers scientific value beyond earlier content, charting new territory for both basic and translational investigators.

WY-14643 (Pirinixic Acid): Biochemical Properties and Research Utility

WY-14643, also known as Pirinixic Acid, is a synthetic ligand characterized by its remarkable specificity and affinity for PPARα, exhibiting an IC₅₀ of 10.11 µM for the human receptor. Structural modifications—such as aliphatic α-substitution—further enhance its agonistic activity, enabling balanced dual PPARα/γ engagement within the lower micromolar range. The compound is a solid, insoluble in water, but dissolves readily in DMSO (≥16.2 mg/mL) and ethanol (≥48.8 mg/mL with ultrasonic assistance). For laboratory use, WY-14643 is supplied by APExBIO as SKU A4305, intended strictly for scientific research and not for clinical application.

Mechanism of Action: WY-14643 as a Selective PPARα Agonist

PPARα is a nuclear receptor pivotal to the regulation of lipid metabolism, energy homeostasis, and inflammation. Upon activation by selective agonists like WY-14643, PPARα forms a heterodimer with the retinoid X receptor (RXR), binding to PPAR response elements (PPREs) in the promoters of target genes. This cascade upregulates genes involved in fatty acid β-oxidation, lipoprotein metabolism, and anti-inflammatory pathways. Intriguingly, α-substituted derivatives of WY-14643 also modulate PPARγ, broadening its utility as a dual PPARα/γ agonist for the study of metabolic crosstalk.

Regulation of Lipid Metabolism and Insulin Sensitivity

Animal studies demonstrate that oral administration of WY-14643 (3 mg/kg/day for 2 weeks) in high fat-fed rats significantly lowers plasma glucose, triglycerides, leptin, muscle triglycerides, and long-chain acyl-CoAs. This is accompanied by reductions in visceral fat and hepatic triglyceride content, culminating in enhanced whole-body insulin sensitivity—with the notable advantage of not promoting weight gain. These metabolic benefits underscore WY-14643’s value as a tool for dissecting the nuances of insulin sensitivity enhancement and lipid metabolism regulation in vivo.

Anti-Inflammatory Activity in Endothelial Cells

WY-14643 exerts potent anti-inflammatory effects in endothelial contexts. Pretreatment with 250 μM of the compound markedly downregulates VCAM-1 expression induced by TNF-α and diminishes monocyte adhesion, highlighting its role as an anti-inflammatory agent in endothelial cells and its relevance to the study of TNF-α mediated inflammation.

Molecular Innovations: YAP-TEAD Mediated PPARα Signaling in Liver Regeneration

While previous literature has predominantly emphasized WY-14643’s impact on immunometabolic signaling and tumor microenvironment remodeling, a seminal study (Wang et al., Capital Medical University & NIH, HEP-21-0169) elucidates a novel axis: the interplay between PPARα activation and YAP-TEAD signaling in liver regeneration. In this research, mice administered with 100 mg/kg/day of WY-14643 exhibited robust hepatomegaly and accelerated liver regeneration following partial hepatectomy (PHx). Importantly, genetic ablation of PPARα or YAP in hepatocytes abolished this regenerative response, firmly establishing the necessity of both factors. The YAP-TEAD transcriptional complex was shown to mediate the proliferative and mitogenic signals downstream of PPARα activation, linking metabolic cues to regenerative outcomes. This breakthrough mechanistic insight expands the potential application of WY-14643 beyond metabolic disorder research into the realms of tissue regeneration and organ repair.

Comparative Analysis: WY-14643 Versus Alternative PPAR Modulators

Compared to other PPARα agonists, such as fenofibrate or gemfibrozil, WY-14643 offers superior selectivity, predictable pharmacokinetics in experimental models, and the ability to modulate both PPARα and PPARγ with specific structural modifications. Unlike thiazolidinediones, which primarily target PPARγ but are associated with adverse effects like fluid retention, WY-14643’s dual activity can be fine-tuned and lacks such liabilities in preclinical studies. Moreover, its capacity to directly influence the YAP-TEAD pathway sets it apart as a unique research tool for exploring hepatic growth and regeneration.

Advanced Applications in Metabolic and Regenerative Research

Deciphering the PPAR Signaling Pathway in Metabolic Disorders

WY-14643 is invaluable for unraveling the PPAR signaling pathway in the context of metabolic syndrome, nonalcoholic fatty liver disease (NAFLD), and type 2 diabetes. By facilitating targeted activation of PPARα, researchers can dissect the transcriptional networks governing lipid catabolism, gluconeogenesis, and inflammatory resolution. These insights inform the development of next-generation therapeutics aimed at restoring metabolic balance without the drawbacks of conventional drugs.

Translational Implications for Liver Regeneration

The discovery that WY-14643-driven PPARα activation promotes liver regeneration via YAP-TEAD reprogramming elevates its translational value. This mechanism provides a foundation for investigating novel interventions in acute liver injury, resection recovery, and potentially chronic hepatic diseases where regenerative capacity is compromised. By leveraging WY-14643 as a research probe, scientists can systematically explore the molecular dialogue between metabolic state and regenerative potential—a frontier largely unexplored in earlier reviews.

Immunometabolic Crosstalk and Inflammation

Building on its recognized anti-inflammatory credentials, WY-14643 enables precise modeling of the intersection between metabolic and immune pathways. Its effects on TNF-α mediated inflammation and endothelial VCAM-1 expression offer robust systems to study the attenuation of chronic inflammation in metabolic disorders and cardiovascular risk.

Content Differentiation and Contextual Interlinking

Much of the existing literature, such as the article "WY-14643 (Pirinixic Acid): Unraveling PPARα/γ Agonism and...", has explored dual agonism and tumor microenvironment remodeling. While these topics are crucial, our current analysis delves deeper into regenerative biology and the molecular mechanics bridging PPARα activation and the YAP-TEAD axis. Similarly, in contrast to "WY-14643 (Pirinixic Acid): PPARα Agonist in Tumor Microen...", which focuses on immunometabolic signaling within the oncological context, our article prioritizes the translational implications for liver repair and metabolic homeostasis. For readers interested in advanced insights connecting metabolic and oncological research, these linked articles provide complementary perspectives, while this piece expands the frontier by elucidating direct regenerative mechanisms and their experimental utility.

Practical Considerations: Storage, Solubility, and Experimental Design

For optimal use in research applications, WY-14643 should be stored at -20°C, with solutions prepared fresh and employed promptly for maximal activity. Its insolubility in water necessitates dissolution in DMSO or ethanol (with ultrasonic assistance as needed). Dosing regimens—from in vitro concentrations (e.g., 250 μM for anti-inflammatory assays) to in vivo administration (3–100 mg/kg/day, context-dependent)—should be tailored to specific experimental aims, always referencing the latest protocols and safety standards.

Conclusion and Future Outlook

WY-14643 (Pirinixic Acid) stands as a versatile and highly selective PPARα agonist for metabolic research, uniquely positioned to advance our understanding of lipid metabolism regulation, insulin sensitivity enhancement, and, most notably, liver regeneration via the YAP-TEAD axis. The recent elucidation of this regenerative mechanism represents a paradigm shift, inviting new inquiries into the convergence of metabolic and regenerative biology. As research progresses, WY-14643—supplied by APExBIO—will remain a cornerstone tool for scientists pursuing breakthroughs in metabolic disorder research, tissue engineering, and beyond.

To learn more or acquire WY-14643 (Pirinixic Acid) from APExBIO for your research, visit the official product page.